MNPR Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of 12.65%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat Electromed, Inc.'s return on equity of 18.89%.

Monopar Therapeutics, Inc. has a consensus price target of $111.77, signalling upside risk potential of 39.05%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Monopar Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Monopar Therapeutics, Inc. is more attractive than Electromed, Inc..

Monopar Therapeutics, Inc. has a beta of 1.456, which suggesting that the stock is 45.554% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Monopar Therapeutics, Inc.'s net income of -$3.4M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of -2.7%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

Monopar Therapeutics, Inc. has a consensus price target of $111.77, signalling upside risk potential of 39.05%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $220.60 which suggests that it could grow by 23.68%. Given that Monopar Therapeutics, Inc. has higher upside potential than iRhythm Technologies, Inc., analysts believe Monopar Therapeutics, Inc. is more attractive than iRhythm Technologies, Inc..

Monopar Therapeutics, Inc. has a beta of 1.456, which suggesting that the stock is 45.554% more volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Monopar Therapeutics, Inc.'s net income of -$3.4M is higher than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 8.07x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of -862.39%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat VolitionRX Ltd.'s return on equity of --.

Monopar Therapeutics, Inc. has a consensus price target of $111.77, signalling upside risk potential of 39.05%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Monopar Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Monopar Therapeutics, Inc..

Monopar Therapeutics, Inc. has a beta of 1.456, which suggesting that the stock is 45.554% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Monopar Therapeutics, Inc.'s net income of -$3.4M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Monopar Therapeutics, Inc.'s net margin of 3.93%. Monopar Therapeutics, Inc.'s return on equity of -31.63% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Monopar Therapeutics, Inc. has a consensus price target of $111.77, signalling upside risk potential of 39.05%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Monopar Therapeutics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Monopar Therapeutics, Inc..

Monopar Therapeutics, Inc. has a beta of 1.456, which suggesting that the stock is 45.554% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Monopar Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monopar Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Monopar Therapeutics, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Monopar Therapeutics, Inc.'s net income of -$3.4M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Monopar Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monopar Therapeutics, Inc. is -- versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.